- Eli Lilly and Company
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Indianapolis, August 17, 2010 (ots/PRNewswire) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary...
- 17.08.2010, 14:01:36
- /
- OTE0006
- Eli Lilly and Company
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
Chicago (ots/PRNewswire) -
- 30.07.2008, 22:22:37
- /
- OTE0007
- Eli Lilly and Company
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Indianapolis (ots/PRNewswire) -
- 31.03.2008, 10:04:09
- /
- OTE0008
Alle Aussendungen
Alle Anhänge
